Floatz logo

(+)-VINCRISTINE

M-Protein

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the M-Protein cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
Liraglutide
University of Miami
Phase 4BB
Inno-206
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3BB
DARATUMUMAB
Hellenic Society of Hematology
Phase 2B
cc-5013
Hellenic Society of Hematology
Phase 1/2CC

View all 11 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →